CerCell

CerCell

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CerCell A/S is a Copenhagen-based developer and manufacturer of customized single-use bioprocessing equipment, operating as a subsidiary of the Swiss Stobbe Group. The company leverages a modular design philosophy to offer configurable single-use bioreactors, fermenters, and mixers, primarily targeting the cell therapy, viral vector, and mRNA production markets. With a focus on flexibility and compatibility with any process control system, CerCell serves pharmaceutical and biotech clients requiring non-standard, small-to-medium scale production solutions. Its technology is rooted in expertise from a European research project on advanced ceramic materials and adherent cell cultivation.

Cell TherapyHematology

Technology Platform

Modular, configurable single-use bioprocessing equipment platform using rigid plastics. Offers tailored assemblies from a library of over 5,000 parts for bioreactors (SUB), fermenters (SUF), and mixers (SUM), compatible with any process control system.

Opportunities

The rapid growth of cell/gene therapies, mRNA production, and personalized medicine creates strong demand for flexible, small-batch bioprocessing equipment.
CerCell's configurable platform is uniquely suited to serve CDMOs and therapy developers with non-standard processes, allowing it to capture a premium niche underserved by large vendors of standardized systems.

Risk Factors

The company's niche focus on high-mix, low-volume customization makes it vulnerable to industry shifts towards standardization.
Managing the complex supply chain for thousands of parts is a logistical and financial risk.
Furthermore, large bioprocessing competitors could develop similar configurable offerings, leveraging their scale and sales reach.

Competitive Landscape

CerCell competes in the single-use bioprocessing market dominated by large corporations like Cytiva (Danaher), Thermo Fisher Scientific, and Sartorius. Its primary competitive advantage is extreme configurability and focus on rigid plastic systems, differentiating it from the bag-based standard offerings of the giants. It likely also competes with smaller specialty firms and in-house engineering solutions at biotech companies.